IR-101 for relapsed or refractory neuroblastoma
Part of Cancer clinical trials.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child's high-risk neuroblastoma has come back or not responded to treatment.
- The tumors must appear on a special scan called a MIBG scan.
- Your child is at least 12 months old.
- Your child has a Lansky score of 50% or higher (meaning they are active more than half the time).
- Your child's organs and blood counts are working well enough.
- No recent treatments like antibody therapy, radiation, or stem cell transplants that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This trial gives a radioactive drug (131I-MIBG) that targets and kills certain nerve tumor cells. It is for people whose neuroblastoma or related tumors have not responded to standard treatments or have come back.
This trial uses a special radioactive medicine (131I-MIBG) to target and kill cancer cells in people with neuroblastoma or pheochromocytoma that has not responded to other treatments. It may help shrink tumors or slow the disease, and you'll receive a stem cell transplant afterward to help your body recover.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.